Oscillatory Devices for the Treatment of Respiratory Conditions
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines Blue Cross Blue Shield of North Carolina's medical necessity coverage, limitations, and coding guidance for oscillatory airway-clearance devices (e.g., Flutter, Acapella, high-frequency chest wall oscillation) used to treat cystic fibrosis, bronchiectasis, neuromuscular disease and other respiratory conditions for BCBSNC members.
Updated coverage criteria to include medically necessary criteria for individuals that have a neuromuscular disorder affecting the ability to cough or clear respiratory secretions.
Information on specific devices moved from Policy Guidelines to the Description section.
Volara™ System added to Regulatory Status and Volara System Oscillation and Lung Expansion listed as investigational.
Clarified rental versus purchase guidance and added billing note to refer to Durable Medical Equipment policy.
Policy Guidelines updated to define chronic bronchiectasis as daily productive cough >=6 months or >2 exacerbations/year and confirmed by chest CT; criteria moved into When Covered.
Coverage Criteria for Oscillatory Airway-Clearance Devices
inv-01: Oscillatory PEP device — general medical necessity
Use of an oscillatory positive expiratory pressure (PEP) device may be considered medically necessary when ALL of the following are met:
Oscillatory PEP examples: Flutter, Acapella
inv-02: High-frequency chest wall oscillation (HFCWO) — rental initial coverage
HFCWO may be considered medically necessary for initial rental when ALL of the following criteria are met:
Chronic diffuse bronchiectasis defined by daily productive cough >=6 months or >2 exacerbations/year and CT confirmation
Must document failure or valid reason
inv-03: HFCWO — purchase after trial
HFCWO may be considered medically necessary for purchase when the following is met:
Appropriate usage defined as daily treatment sessions for an absolute minimum of 15 minutes per session; written confirmation required for purchase.
inv-04: When Covered
Covered when ALL of the following are met (for specific devices as stated):
From When Covered; see policy definition of chronic diffuse bronchiectasis
Includes requirement for CT confirmation and documented exacerbations per chronic bronchiectasis definition
Updated effective 10/1/2024 to include neuromuscular disorders
inv-05: When Not Covered / Investigational
Not covered or investigational when any of the following apply:
May be denied; no data show added benefit over conventional chest physical therapy
May be denied as investigational
Listed investigational in policy updates
Use of high-frequency chest wall compression (HFCWC) devices and intrapulmonary percussive ventilation (IPV) devices for indications other than those specifically listed in the policy is considered investigational. Examples of applications considered investigational include their use as an adjunct to chest physical therapy and use in other lung diseases such as chronic obstructive pulmonary disease (COPD). These investigational uses are excluded from coverage and may be denied if billed for these indications.
The Volara System Oscillation and Lung Expansion (OLE) 3-in-1 combined therapy device is explicitly listed in the policy as investigational. As such, claims for the Volara OLE device for oscillation and lung expansion therapy are excluded from coverage under this policy.
Use of oscillatory airway-clearance devices, including HFCWO and IPV systems, as an adjunct to chest physical therapy or for other pulmonary conditions not specified in the policy (for example, COPD) is considered investigational and is excluded from coverage. Providers should not expect coverage when these devices are prescribed solely to supplement standard chest physiotherapy or to treat lung diseases outside the policy’s specified indications.
High-frequency chest wall compression devices are considered not medically necessary when used as an alternative to chest physical therapy in patients with cystic fibrosis or chronic bronchiectasis in clinical situations other than those explicitly specified in the policy. The policy notes that there are no clinical data showing additional health benefit of these devices compared to conventional chest physical therapy in such unspecified situations, and requests for coverage may be denied.
For patients with cystic fibrosis (CF) or chronic bronchiectasis, use of high-frequency chest wall compression devices as an alternative to standard chest physical therapy is covered only under the specific clinical circumstances defined in the policy. Use of these devices outside those defined indications—such as routine substitution for conventional chest physiotherapy without documented criteria being met—is considered not medically necessary and may be denied.
Billing, Procedure, and Supply Codes
| 94669 | Not specified in document (listed applicable) |
| A7021 | Not specified in document (listed applicable) |
| A7025 | Not specified in document (listed applicable) |
| A7026 | Not specified in document (listed applicable) |
| E0469 | Not specified in document (listed applicable) |
| E0480 | Not specified in document (listed applicable) |
| E0481 | Not specified in document (listed applicable) |
| E0483 | Not specified in document (listed applicable) |
| E0484 | Not specified in document (listed applicable) |
| S8185 | Not specified in document (listed applicable) |
Prior Authorization, Documentation, and Provider Requirements
Prior authorization and DME supplier rules
Prior authorization and determinations about rental versus purchase follow Durable Medical Equipment (DME) policies; devices are covered only when the policy's medical necessity criteria are met, including diagnosis, failed/unavailable conventional therapy, specialist prescription, and trial requirements. The DME supplier must meet Plan eligibility/credentialing requirements to be eligible for reimbursement.
- Coverage and rental vs purchase decisions guided by DME policy.
- Device coverage requires meeting all medical necessity criteria (diagnosis, failed/unavailable conventional therapy, specialist prescription, trial).
- DME supplier must meet Plan eligibility/credentialing requirements.
Step requirement before HFCWO
Approval for high-frequency chest wall oscillation (HFCWO) requires demonstration of failure of or inability to use conventional manual chest physiotherapy; if appropriate, prior use (and failure) of an oscillatory PEP device should also be documented before HFCWO is authorized.
- Conventional manual chest PT must be unavailable, ineffective, or not tolerated with documented failure.
- If appropriate, documented failure of an oscillatory PEP device (e.g., Flutter/Acapella) is required prior to HFCWO.
Document failure of standard treatments
Document in the medical record that standard treatments (for example, chest physiotherapy and, if appropriate, Flutter or Acapella oscillatory PEP devices) were attempted and failed or provide valid reasons why standard chest physiotherapy cannot be performed.
- Record attempts and failure of chest physiotherapy.
- Document prior use and failure of oscillatory PEP devices when applicable or explain why they were not used.
Required clinical documentation for medical necessity
Clinical documentation submitted for medical necessity must include the diagnosis, demonstration of bronchopulmonary secretions and need for airway clearance, evidence of failed or intolerant conventional chest physiotherapy (or reason it is unavailable), specialist prescription (pulmonologist or cystic fibrosis clinic), and for purchase requests, written confirmation of a successful 4-month trial with appropriate usage (minimum 15 minutes per session).
- Diagnosis and demonstrated need for airway clearance (bronchopulmonary secretions).
- Documentation of failed/unavailable/intolerant conventional chest physiotherapy or valid reasons it cannot be performed.
- Prescription by a pulmonologist or cystic fibrosis clinic.
- For purchase: written confirmation of successful 4-month trial and compliance (>=15 minutes per session).
Documentation requirements for chronic bronchiectasis
For chronic bronchiectasis, include documentation that meets the policy definition: daily productive cough for at least 6 continuous months or more than two exacerbations per year requiring antibiotic therapy, plus confirmation by high-resolution or spiral chest CT scan.
- Daily productive cough ≥ 6 continuous months OR >2 exacerbations/year requiring antibiotics.
- Confirmation of bronchiectasis by high-resolution or spiral chest CT scan.
Medical records may be requested — risk of denial if not provided
BCBSNC may request medical records to determine medical necessity; failure to provide the requested records or the required documentation may result in denial of coverage.
- Provide complete medical records when requested; letters alone are insufficient unless all required information is included.
- Lack of required documentation can lead to denial.
Use limitations — avoid non‑specified indications
Do not submit claims for HFCWO, intrapulmonary percussive ventilation, or related devices for indications outside those specified in the policy (including use as an adjunct to chest physical therapy or in other lung diseases such as COPD) because such uses are considered investigational and may be denied.
- Uses as adjunct to chest physical therapy are investigational.
- Use in other lung diseases (e.g., COPD) is investigational and may be denied.
Not medically necessary — alternatives to chest physical therapy
High-frequency chest wall compression devices are considered not medically necessary as an alternative to chest physical therapy in patients with cystic fibrosis or chronic bronchiectasis in clinical situations other than those specified; submitting these as alternatives outside the policy may result in denial.
- Do not request coverage as an alternative to chest physical therapy in unspecified clinical situations.
- Such requests are considered not medically necessary and may be denied.
Background and Device Description
Oscillatory airway-clearance devices generate either airflow oscillations or external chest wall oscillations to help loosen and mobilize airway secretions. They range from handheld oscillatory positive expiratory pressure (PEP) devices (for example, Flutter and Acapella) that require active patient participation to passive systems such as high-frequency chest wall oscillation vests that apply external compression. These devices are intended to be alternatives to percussion and postural drainage and may be used in conditions with excessive mucus production—such as cystic fibrosis, diffuse bronchiectasis, and certain neuromuscular disorders—when conventional chest physiotherapy is ineffective, not tolerated, or unavailable.
Key Definitions
Policy Revision History
Updated Description and Regulatory Status; references added; Specialty Matched Consultant Advisory Panel and Medical Director reviews in 3/2026; no changes to policy statement.
Minor updates to Policy Guidelines and references added; Specialty Matched Consultant Advisory Panel and Medical Director reviews in 3/2025 with no changes to policy statement.
Clarified the When Not Covered section for consistency with the When Covered section.
Coverage criteria updated to include medically necessary criteria for individuals with neuromuscular disorders affecting cough/clearance; billing codes A7021 and E0469 added to Billing/Coding effective 10/1/2024.
Policy Guidelines updated for clarity and references added; Specialty Matched Consultant Advisory Panel and Medical Director reviews in 3/2024 with no changes to policy statement.
Regulatory status and Policy Guidelines updated; references added; Specialty Matched Consultant Advisory Panel and Medical Director reviews in 3/2023 with no changes to policy statement.
When Covered section clarified for rental versus purchase guidance and Billing/Coding note added to refer to Durable Medical Equipment policy.
References added; Specialty Matched Consultant Advisory Panel and Medical Director reviews in 3/2022 with no changes to policy statement.
Policy noticed 6/15/2021 for effective date 8/24/2021; Volara System added to Regulatory Status and Volara System Oscillation and Lung Expansion listed as investigational earlier in 6/15/2021 updates.
Specialty Matched Consultant Advisory Panel review 3/30/2016; miscellaneous wording changes across policy (2016–2017 updates recorded).
Description section extensively revised and coverage statements reorganized; When Covered section replaced to clarify indications and requirements for FLUTTER/Acapella and HFCWO/IPV devices.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.